title: Dynamic imaging of emerging resistance during cancer therapy.
abstract: One of the greatest challenges in developing therapeutic regimens is the inability to rapidly and objectively assess tumor response due to treatment. Moreover, tumor response to therapeutic intervention in many cases is transient, and progressive alterations within the tumor may mask the effectiveness of an initially successful therapy. The ability to detect these changes as they occur would allow timely initiation of alternative approaches, maximizing therapeutic outcome. We investigated the ability of diffusion magnetic resonance imaging (MRI) to provide a sensitive measure of tumor response throughout the course of treatment, possibly identifying changes in sensitivity to the therapy. Orthotopic 9L gliomas were subjected to two separate therapeutic regimens, with one group receiving a single 5-day cycle (1omega) of low-dose 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and a second group receiving two cycles at the same dose, bisected with 2 days of rest (2omega). Apparent diffusion coefficient maps were acquired before and throughout treatment to observe changes in water mobility, and these observations were correlated to standard measures of therapeutic response and outcome. Our results showed that diffusion MRI was indeed able to detect the emergence of a drug-resistant tumor subpopulation subsequent to an initially successful cycle of BCNU therapy, leading to minimal gains from a second cycle. These diffusion MRI findings were highly correlated with tumor growth delay, animal survival, and ex vivo growth inhibition assays showing emerging resistance in excised tumors. Overall, this study highlights the ability of diffusion MRI to provide sensitive dynamic assessment of therapy-induced response, allowing early opportunities for optimization of therapeutic protocols.
authors.affiliation: Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: Kuei C
authors.initials: KC
authors.lastname: Lee
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Hall
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Hoff
authors.forename: Bradford A
authors.initials: BA
authors.lastname: Moffat
authors.forename: Surabhi
authors.initials: S
authors.lastname: Sharma
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Chenevert
authors.forename: Charles R
authors.initials: CR
authors.lastname: Meyer
authors.forename: Wilbur R
authors.initials: WR
authors.lastname: Leopold
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Johnson
authors.forename: Richard V
authors.initials: RV
authors.lastname: Mazurchuk
authors.forename: Alnawaz
authors.initials: A
authors.lastname: Rehemtulla
authors.forename: Brian D
authors.initials: BD
authors.lastname: Ross
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002330:Carmustine / Q000008:administration & dosage*; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D002330:Carmustine